Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 2 Recurrence 1 Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 25 fludarabine 19 Dexamethasone 17 pembrolizumab 13 Rituximab 12 venetoclax 9 Lenalidomide 9 Gemcitabine 9 Etoposide 9 pomalidomide 8 Vincristine 7 glofitamab 6 fludarabine phosphate 6 carfilzomib 6 Temozolomide 6 obinutuzumab 5 daratumumab 5 Prednisone 5 Nivolumab 5 Doxorubicin 5 Cisplatin 5 Calcium Dobesilate 5 Bortezomib 5 zanubrutinib 4 selinexor 4 Immunotherapy, Adoptive 4 Cytarabine 4 Carboplatin 4 Azacitidine 4 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Clarithromycin × 90 days × Clear all

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡